Evonik launches plant-derived squalene

In Germany, Evonik has launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene on the market for use in adjuvants in parenteral dosage forms. It meets the demand for a secure commercial supply of non-animal-derived squalene. Non-GMP samples of PhytoSquene® are available immediately with GMP quality to follow in 2023.

With the launch of PhytoSquene®, Evonik offers an alternative to animal-derived squalene, which for pharmaceutical applications is typically sourced from shark liver oil.